Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment

BACKGROUND: This multicentre, open-label study evaluated the efficacy and safety of SPI-1620, an analogue of endothelin-1, administered in combination with docetaxel as second-line treatment for patients with advanced biliary tract cancer (ABTC). METHODS: Eligible patients received continuous cycles...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Richard, Chiorean, E Gabriela, Amin, Manik, Rocha-Lima, Caio Max S, Gandhi, Jitendra, Harris, William P, Song, Tao, Portnoy, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520510/
https://www.ncbi.nlm.nih.gov/pubmed/28632730
http://dx.doi.org/10.1038/bjc.2017.160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520510/
https://www.ncbi.nlm.nih.gov/pubmed/28632730
http://dx.doi.org/10.1038/bjc.2017.160

Ejemplares similares